You are here

Dynasore Analogues for Ocular Surface Protection

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41EY030811-01
Agency Tracking Number: R41EY030811
Amount: $447,294.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NEI
Solicitation Number: PA18-575
Timeline
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-09-01
Award End Date (Contract End Date): 2021-07-31
Small Business Information
99 HAYDEN AVE STE 210
Lexington, MA 02421-7965
United States
DUNS: 786461967
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 TSVETELINA LAZAROVA
 (781) 676-2000
 tlazarova@medchempartners.com
Business Contact
 TSVETELINA LAZAROVA
Phone: (781) 279-3088
Email: tlazarova@medchempartners.com
Research Institution
 TUFTS MEDICAL CENTER
 
800 WASHINGTON ST
BOSTON, MA 02111-1552
United States

 Domestic nonprofit research organization
Abstract

7. PROJECT SUMMARY
Diseases of the ocular surface are among the top reasons for visits to eye care practitioners. These conditions
can severely affect eyesight and quality of life. Symptoms may include blurry vision, discomfort or pain,
redness and itching, and in severe cases, blindness due to corneal scarring. Many ocular surface diseases are
initiated by loss of tear film homeostasis and can be grouped under a syndrome known as dry eye. Tear
dysfunction leading to desiccating stress, initiates an autoimmune-like “vicious cycle of inflammation” that
damages the ocular surface barrier. The vicious cycle is recognized as the core driver of the pathologic
process, leading to chronic dry eye disease. Anti-inflammatory steroids and small molecules targeting
autoimmune T-cell function are currently the only Food and Drug Administration (FDA)-approved therapeutics.
These drugs are not effective in all patients, take a long time to work, and have unpleasant side effects.
Current opinion holds that breaking the inflammatory vicious cycle at alternative entry points is the key to new
treatments. Direct protection of the ocular surface barrier could provide such a new entry point. This should
relieve chronic dry eye by ramping down the inflammatory vicious cycle, like current therapeutics. However,
because it represents a different entry point, it may be efficacious in chronic situations where current drugs do
not work. A novel benefit is the potential for very rapid relief of eye irritation in situations where dry eye is
exacerbated by environmental, and other factors. In a recent publication, the academic lab associated with this
project reported the novel discovery that Dynasore and Dyngo-4A are remarkably protective of the ocular
surface barrier. Dynasore and Dyngo-4A belong to a group of small molecules targeting dynamin family
GTPases, which also protect cells and tissues against oxidative stress and reduce inflammatory cytokine
production. The innovation of Dynasore analogues for dry eye is that they target ocular surface barrier
damage. There are no such therapeutics available at this time that act at this point in the vicious cycle. The
long-term goal of this project is development of a novel FDA-approved drug based on Dynasore compounds.
This phase I program will proceed via three Specific Aims: 1) prepare a Dynasore analogue library to define
structure-activity relationships; 2) test analogues for activity in a validated human cell culture model of the
ocular surface; 3) provide proof-of-concept using a relevant mouse model for chronic dry eye. Following
completion of this phase I effort, the team will have selected a lead compound as a potential treatment for
ocular surface disease in dry eye. During phase II, additional compounds will be prepared to fine-tune efficacy
and pharmacokinetic properties and animal testing will be expanded to examine toxicity or eye irritation, and
look for systemic exposure. Finally, formulation and dosage will be fine-tuned to maximize efficacy, shelf life
and ease of application, while decreasing any toxic or off target effects that may arise.8. PROJECT NARRATIVE
Dry eye is a global problem, afflicting over 30 million people in the United States alone, and at least 344 million
people worldwide. Prevalence is higher among women than men and increases with age, but is also notable
among the 18-34-year age group. It has been estimated that the overall burden of dry eye for the US
healthcare system is $3.84 billion. These facts underpin the great need for new treatments.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government